The U.S. Food and Drug Administration (FDA) has granted fast track designation to Alessa Therapeutics for its lead product ...

Prostate cancer (PCa) is one of the most common malignant tumors among men worldwide. Following androgen deprivation therapy ...

Thousands of men in England living with advanced prostate cancer are poised to benefit from a new life-extending drug, ...

Chemotherapy uses medicines to kill fast-growing cells (like cancer cells) or to keep them from dividing (which is how cancers grow). It is a systemic treatment which means the medicines will travel ...

Decades ago, doctors created a test to determine which breast cancer patients should receive hormone therapy. Now, ...

Survivorship in metastatic prostate cancer is seen as chronic management, focusing on quality of life through physical and emotional management. Carotuximab combined with Erleada shows a favorable ...

In preclinical prostate cancer models, HLD-0915 treatment resulted in tumor shrinkage and declines in prostate-specific antigen. The Food and Drug Administration (FDA) has granted Fast Track ...

TORONTO — Ontario is expanding access to six new cancer drugs through a pilot program designed to speed up public funding ...

Every prostate cancer journey begins with a clear understanding of the diagnosis. This isn’t a “one-size-fits-all” disease, and treatment plans are highly personalized. “When we’re evaluating a case ...

Patients will be able to find out whether they have genes linked to cancer using a world-leading tool developed by the NHS.